Description
“With no one brand dominating the Molecular IVD market and a fragmented market in terms of market share by technique, there is an opportunity for both brand growth and expansion with careful planning and investment.”
There are a variety of Molecular Diagnostic (MDx) techniques used in hospitals, research labs, clinics, and commercial reference labs that are used to detect nucleic acids and proteins for diagnostic or monitoring purposes. Most require an analytical instrument, such as a PCR machine, mass spectrometer, or sequencer. While MDx techniques evolve in different ways and not all methods survive, those that do typically transition from basic research to lab developed tests (LDTs) in applied testing and diagnostic markets, where they are able to be used in a more routine and trusted capacity.
In this report, we present a thorough picture of the MDx market – its current situation, trends, recent market-oriented data about analytical solutions being used in this field, as well as future growth projections. This report does not aim to be exhaustive, but it does provide information on those techniques where innovation in established technology platforms is most applicable to clinical diagnostics. Thus, the scope of this report is not limited to nucleic acid-based techniques (amplification, sequencing, microarrays and in situ hybridization), but also includes mass spectrometry and HPLC for the analysis of proteins, hormones, drugs, and other complex, bioactive molecules.
The MDx market has two major segments: clinical research and molecular in vitro diagnostics (IVD). Clinical research involves the development of assays for molecular diagnostics, biomarker discovery, and pharmacogenomic applications. Molecular IVD embodies the analysis and detection of infectious disease, cancer, genetic disorders, metabolic ailments, and others. It represents about one-tenth of the IVD market and is the fastest growing segment within IVD.
With the data of this report in hand, you can compare your brand’s market penetration to your competitors, as well as identify growth segments where you have presence, but no brand leader has yet been established. Confidently steer future marketing efforts and focus resources on segments that make the most sense for your overall (or niche) MDx growth strategy.
Companies mentioned in this report:
- Abbott
- Agilent
- Agena Bioscience
- Alere
- Arkray
- BD
- bioMérieux
- Bio-Rad
- Bio-Techne
- BGI
- Bruker
- Cepheid
- Erba
- Hologic
- Illumina
- Leica Biosystems
- Luminex
- MD Diagnostics
- Merck
- Molecular Devices
- OGT
- PerkinElmer
- QIAGEN
- Roche Diagnostics
- SCIEX
- Shimadzu
- Tecan
- Thermo Fisher
- TOSOH
- Waters
Please download the complimentary Report Brochure (upper left corner of your screen) to review the detailed objectives, table of contents, and sample data.
For additional questions, please contact:
Devin Holland
703.778.3080 x19
reports@gene2drug.com
